{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:13:41Z","timestamp":1761560021559,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","funder":[{"DOI":"10.13039\/100007816","name":"Alcon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007816","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s12325-016-0297-6","type":"journal-article","created":{"date-parts":[[2016,2,9]],"date-time":"2016-02-09T09:22:06Z","timestamp":1455009726000},"page":"435-446","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma"],"prefix":"10.1007","volume":"33","author":[{"given":"Tomoko","family":"Naito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Nagayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Mizoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mineo","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Namiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Tanito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,9]]},"reference":[{"key":"297_CR1","first-page":"1641","volume":"111","author":"A Iwase","year":"2004","unstructured":"Iwase A, Suzuki Y, Yamamoto T, et al. The prevalence of primary open-angle glaucoma in Japanese. The Tajimi Study. Ophthalmology. 2004;111:1641\u20138.","journal-title":"Ophthalmology."},{"key":"297_CR2","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.ophtha.2005.05.012","volume":"112","author":"T Yamamoto","year":"2005","unstructured":"Yamamoto T, Iwase A, Arai M, et al. The Tajimi Study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology. 2005;112:1661\u20139.","journal-title":"Ophthalmology"},{"key":"297_CR3","unstructured":"Japan Glaucoma Society Guidelines for Glaucoma (3rd edition). [Article in Japanese] Nihon Ganka Gakkai Zasshi 2012;116:7\u201346."},{"key":"297_CR4","unstructured":"American Academy of Ophthalmology. Summary benchmarks for preferred practice pattern\u00ae guidelines. http:\/\/www.aao.org . Accessed 22 Sept 2015."},{"key":"297_CR5","doi-asserted-by":"crossref","unstructured":"The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429\u201340.","DOI":"10.1016\/S0002-9394(00)00538-9"},{"key":"297_CR6","doi-asserted-by":"crossref","unstructured":"Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:498\u2013505.","DOI":"10.1016\/S0002-9394(98)00272-4"},{"key":"297_CR7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10384-009-0779-z","volume":"54","author":"A Aoyama","year":"2010","unstructured":"Aoyama A, Ishida K, Sawada A, Yamamoto T. Target intraocular pressure for stability of visual field loss progression in normal-tension glaucoma. Jpn J Ophthalmol. 2010;54:117\u201323.","journal-title":"Jpn J Ophthalmol"},{"key":"297_CR8","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2147\/OPTH.S86450","volume":"9","author":"T Naito","year":"2015","unstructured":"Naito T, Yoshikawa K, Mizoue S, et al. Relationship between progression of visual field defect and intraocular pressure in primary open-angle glaucoma. Clin Ophthalmol. 2015;9:1373\u20138.","journal-title":"Clin Ophthalmol."},{"key":"297_CR9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00061198-200004000-00002","volume":"9","author":"S Asrani","year":"2000","unstructured":"Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134\u201342.","journal-title":"J Glaucoma"},{"key":"297_CR10","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.ophtha.2007.10.031","volume":"115","author":"J Caprioli","year":"2008","unstructured":"Caprioli J, Coleman A. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008;115:1123\u20139.","journal-title":"Ophthalmology"},{"key":"297_CR11","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1089\/jop.2014.0034","volume":"30","author":"J Shin","year":"2014","unstructured":"Shin J, Lee JW, Choi BS, et al. The circadian changes of intraocular pressure and ocular perfusion pressure after tafluprost compared with travoprost in normal tension glaucoma. J Ocul Pharmacol Ther. 2014;30:803\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"key":"297_CR12","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0002-9394(01)01177-1","volume":"132","author":"PA Netland","year":"2001","unstructured":"Netland PA, Randry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472\u201384.","journal-title":"Am J Ophthalmol"},{"key":"297_CR13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ophtha.2006.07.064","volume":"114","author":"AG Konstas","year":"2007","unstructured":"Konstas AG, Kozobolis VP, Katsimpris IE, et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology. 2007;114:653\u20137.","journal-title":"Ophthalmology"},{"key":"297_CR14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0149-2918(04)90008-2","volume":"26","author":"HB Dubiner","year":"2004","unstructured":"Dubiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther. 2004;26:84\u201391.","journal-title":"Clin Ther"},{"key":"297_CR15","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2147\/OPTH.S61444","volume":"9","author":"L Quaranta","year":"2015","unstructured":"Quaranta L, Riva I, Katsanos A, Floriani I, Centofanti M, Konstas AG. Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure. Clin Ophthalmol. 2015;9:633\u201343.","journal-title":"Clin Ophthalmol."},{"key":"297_CR16","doi-asserted-by":"crossref","unstructured":"Dubiner HB, Noecker R. Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%. Clin Ophthalmol. 2012;6:525\u201331.","DOI":"10.2147\/OPTH.S30690"},{"key":"297_CR17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/IJG.0000000000000073","volume":"23","author":"I Riva","year":"2014","unstructured":"Riva I, Katsanos A, Floriani I, et al. Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma. J Glaucoma. 2014;23:535\u201340.","journal-title":"J Glaucoma"},{"key":"297_CR18","first-page":"643","volume":"4","author":"Y Nomura","year":"2010","unstructured":"Nomura Y, Nakakura S, Moriwaki M, Takahashi Y, Shiraki K. Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma. Clin Ophthalmol. 2010;4:643\u20137.","journal-title":"Clin Ophthalmol."},{"key":"297_CR19","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2147\/OPTH.S73125","volume":"8","author":"LK Seibold","year":"2014","unstructured":"Seibold LK, Kahook MY. The diurnal and nocturnal effects of travoprost in normal-tension glaucoma. Clin Ophthalmol. 2014;8:2189\u201393.","journal-title":"Clin Ophthalmol."},{"key":"297_CR20","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s12325-010-0070-1","volume":"27","author":"AA David","year":"2010","unstructured":"David AA, Robert JN, Malik YK. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010;27:837\u201345.","journal-title":"Adv Ther."},{"issue":"1","key":"297_CR21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/01.ijg.0000212274.50229.c6","volume":"16","author":"RA Lewis","year":"2007","unstructured":"Lewis RA, Katz G, Weiss MJ, et al. Travoprost BAC-free Group. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16(1):98\u2013103.","journal-title":"J Glaucoma"},{"key":"297_CR22","first-page":"221","volume":"21","author":"MA Lemp","year":"1995","unstructured":"Lemp MA. Report of the National Eye Institute\/industry workshop on Clinical Trials in Dry Eyes. CLAO J. 1995;21:221\u201332.","journal-title":"CLAO J"},{"key":"297_CR23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10384-009-0754-8","volume":"54","author":"S Yamazaki","year":"2010","unstructured":"Yamazaki S, Nanno M, Kimura T, Suzumura H, Yoshikawa K. Effects of switching to SofZia-preserved travoprost in patients who presented with superficial punctate keratopathy while under treatment with latanoprost. Jpn J Ophthalmol. 2010;54:7\u201314.","journal-title":"Jpn J Ophthalmol"},{"key":"297_CR24","doi-asserted-by":"crossref","unstructured":"Mizoue S, Nakano T, Fuse N, Iwase A, Matsumoto S, Yoshikawa K. Travoprost with sofZia\u00ae preservative system lowered intraocular pressure of Japanese normal tension glaucoma with minimal side effects. Clin Ophthalmol. 2014;8:347\u201354.","DOI":"10.2147\/OPTH.S57640"},{"key":"297_CR25","unstructured":"SAS Institute Inc.: SAS\/STAT\u00ae 9.2 User\u2019s Guide: The Mixed Procedure; 2008."},{"issue":"8","key":"297_CR26","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/bjo.2007.135269","volume":"92","author":"GS Ang","year":"2008","unstructured":"Ang GS, Kersey JP, Shepstone L, Broadway DC. The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomised controlled trial. Br J Ophthalmol. 2008;92(8):1129\u201333.","journal-title":"Br J Ophthalmol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0297-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T01:32:01Z","timestamp":1498267921000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0297-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,9]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["297"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0297-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2016,2,9]]}}}